Skip to content

Study · Animal study (in vivo) · mouse · 1982

3 results

Increase of mouse resistance to Candida albicans infection by thymosin alpha 1.

Bistoni F, Marconi P, Frati L, Bonmassar E, Garaci E

Infection and immunity1 May 1982Cited by 31 (Europe PMC)

PMID7085074 (opens in a new tab)PMCIDPMC351272 (opens in a new tab)DOI10.1128/iai.36.2.609-614.1982 (opens in a new tab)PepBankPUB-07085074
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, thymosin alpha‑1 at 100 micrograms/kg given before, or before and after, C. albicans challenge gave significant resistance to lethal infection.

    In plain wordsIn mice, thymosin alpha‑1 given before a fungal infection raised resistance to a lethal infection.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseSurvival after C. albicans challenge with pretreatment
    Study

    mousen: not reported in source

    Candida albicans lethal infection
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    100 micrograms/kgAs given in this study (mouse).

    Source sentences

    Summary
    Significant resistance ot lethal infection was afforded by 100 micrograms of thymosin alpha 1 per kg given before or before and after challenge
    1 context sentence
    Summary · context
    Two- to four-month-old mice were treated with graded doses of thymosin alpha 1 before, after, or before and after intravenous challenge with C. albicans.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, thymosin alpha‑1 given only after C. albicans inoculation gave no protection at any dose level.

    In plain wordsIn mice, thymosin alpha‑1 given only after a fungal infection began gave no protection.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeSurvival after C. albicans challenge with treatment after inoculation
    Study

    mousen: not reported in source

    Candida albicans lethal infection
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    graded dosesAs given in this study (mouse).

    Source sentences

    Summary
    whereas no protection was found in mice treated with thymosin alpha 1 administered at any dose level after inoculation.
    1 context sentence
    Summary · context
    Two- to four-month-old mice were treated with graded doses of thymosin alpha 1 before, after, or before and after intravenous challenge with C. albicans.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice pretreated with cyclophosphamide, pretreatment with thymosin alpha‑1 prevented the increased susceptibility to C. albicans infection.

    In plain wordsIn mice weakened by cyclophosphamide, thymosin alpha‑1 given beforehand prevented the higher risk of fungal infection.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseSusceptibility to C. albicans in cyclophosphamide-pretreated mice
    Study

    mousen: not reported in source

    Candida albicans lethal infection
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pretreatment with thymosin alpha 1 also prevented the increased susceptibility to C. albicans infection of mice pretreated with cyclophosphamide on day -6.
    1 context sentence
    Summary · context
    Two- to four-month-old mice were treated with graded doses of thymosin alpha 1 before, after, or before and after intravenous challenge with C. albicans.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.